RT Journal Article
SR Electronic
T1 Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.11.23292344
DO 10.1101/2023.07.11.23292344
A1 Delgado, Ana Lledo
A1 Preston-Hurlburt, Paula
A1 Lim, Noha
A1 Sumida, Tomokazu S.
A1 Long, S. Alice
A1 McNamara, James
A1 Serti, Elisavet
A1 Higdon, Lauren
A1 Herold, Kevan C.
YR 2023
UL http://medrxiv.org/content/early/2023/07/13/2023.07.11.23292344.abstract
AB Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment. Higher number of Tregs and partially exhausted CD8+ T cells were found in EBV seropositive individuals at the baseline in the TN10 trial and AbATE trial. Single cell transcriptomics and functional assays identified downregulation of the T cell receptor and other signaling pathways before treatment. Impairments in function of adaptive immune cells were enhanced by teplizumab treatment in EBV seropositive individuals. Our data indicate that EBV can impair signaling pathways generally in immune cells, that broadly redirect cell differentiation.Competing Interest StatementKH is a co-inventor on a patent for the use of teplizumab for delay of Type 1 diabetes. Supported by grants DK057846 and AI66387 to KH. Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding StatementKH is a co-inventor on a patent for the use of teplizumab for delay of Type 1 diabetes. Supported by grants DK057846 and AI66387 to KH. Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by the Institutional Review Boards at the study sites. The Institutional Review Boards at the following locations gave ethical approval: For the TN10 protocol: Children's Mercy Hospital, Overland Park, KS USA Vanderbilt University, Nashville, TN USA, University of Florida, Gainesville, FL USA, Yale University, New Haven, CT USA, University of Miami, Miami, FL USA Barbara Davis Center, University of Colorado, Anshutz, CO, USA, University of Minnesota, Minneapolis, MS USA, University of California- San Francisco, San Francisco, CA USA, Hospital for Sick Children, Toronto Canada, University of Iowa, Iowa City, IA USA, University of South Florida, Tampa, FL USA, Forschergruppe Diabetes, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany. For the AbATE protocol: Yale University, New Haven, CT USA, University of California San Francisco, San Francisco, CA USA, University of Colorado, Anshutz, CO USA, Benaroya Research Center, Seattle, WA, University of Washington, Seattle, WA. All study participants gave written consent or assent for use of their samples for mechanistic studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors